Appendix cancer future or investigational therapies

Genetic studies revolutionized cancer treatment; appendix cancer is not an exception. Traditionally appendiceal cancers were approached the same as colorectal cancers. Recent genetic studies demonstrated that appendiceal tumors are clearly differ from colorectal cancers. Furthermore, It has been shown that mutation profiles are associated with the patients’ prognosis.

• Genetic studies revolutionized cancer treatment; appendix cancer is not an exception.
• Traditionally appendiceal cancers were approached the same as colorectal cancers.
  • Recent genetic studies demonstrated that appendiceal tumors are clearly differ from colorectal cancers. ^[1]
  • Presence of mutated TP53 and APC genes were significantly lower in appendiceal cancers compared to colorectal cancers.
• It has been shown that mutation profiles are associated with the patients’ prognosis. ^[2]
  • Mutations in the TP53 significantly decrease life expectancy in patients with appendix cancer.
  • Regardless of tumor grade, TP53 mutations were associated with poorer outcomes.
  • Patients with GNAS mutations had a life expectancy of 10 years after diagnosis.
  • Appendiceal tumors with GNAS mutations rarely develop into high-grade tumors.